Brief: Medicinova Says Secondary Analysis Of Phase 2 Trial Of Mn-166 Showed Mn-166 Reduces Rates Of Heavy Drinking And Measures Of Alcohol Craving
08/04/2022 24:04
April 7 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA - SECONDARY ANALYSIS OF PHASE 2 TRIAL OF MN-166
SHOWED MN-166 REDUCES RATES OF HEAVY DRINKING AND MEASURES OF
ALCOHOL CRAVING
Source text for Eikon: ID:nGNX1lnJWV
Further company coverage: MNOV.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake